| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.17▲ | 1.18▲ | 1.17▲ | 1.17▲ | 1.24▼ |
| MA10 | 1.17▲ | 1.17▲ | 1.15▲ | 1.19▲ | 1.36▼ |
| MA20 | 1.15▲ | 1.16▲ | 1.17▲ | 1.26▼ | 1.50▼ |
| MA50 | 1.18▲ | 1.20▲ | 1.21▼ | 1.39▼ | 2.06▼ |
| MA100 | 1.21▼ | 1.25▼ | 1.29▼ | 1.53▼ | 3.32▼ |
| MA200 | 1.28▼ | 1.37▼ | 1.40▼ | 1.77▼ | 7.76▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | 0.009▲ | 0.007▲ | -0.001▼ | 0.004▲ |
| RSI | 57.699▲ | 55.304▲ | 53.838▲ | 41.931▼ | 33.977▼ |
| STOCH | 54.295 | 74.881 | 67.149 | 33.598 | 14.595▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -49.544 | -79.210▼ |
| CCI | 114.027▲ | 124.484▲ | 132.110▲ | -18.118 | -127.234▼ |
|
Wednesday, November 19, 2025 03:00 AM
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, ...
|
|
Wednesday, November 12, 2025 05:25 PM
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while ...
|
|
Friday, October 24, 2025 05:31 AM
DOYLESTOWN, Pa., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/11/25 | 1.20 | 1.205 | 1.20 | 1.205 | 7,769 |
| 24/11/25 | 1.24 | 1.2499 | 1.1386 | 1.17 | 22,338 |
| 21/11/25 | 1.11 | 1.17 | 1.0777 | 1.17 | 30,699 |
| 20/11/25 | 1.18 | 1.2299 | 1.10 | 1.11 | 85,875 |
| 19/11/25 | 1.21 | 1.2771 | 1.17 | 1.20 | 44,218 |
| 18/11/25 | 1.18 | 1.2199 | 1.15 | 1.19 | 61,609 |
| 17/11/25 | 1.20 | 1.25 | 1.15 | 1.19 | 22,134 |
| 14/11/25 | 1.18 | 1.24 | 1.1528 | 1.21 | 41,751 |
| 13/11/25 | 1.23 | 1.245 | 1.17 | 1.19 | 607,912 |
| 12/11/25 | 1.28 | 1.29 | 1.2302 | 1.26 | 29,574 |
|
|
||||
|
|
||||
|
|